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The purpose of this policy brief is to inform the debate from a health perspective in the final stages 
of the negotiations on the Trans Pacific Partnership Agreement (TPPA), particularly during meetings 
of chief negotiators and ministers in February 2014. 
This policy brief outlines the evidence about the potential health effects on the Australian 
community of actions related to the TPPA, based on publicly available and recently leaked 
negotiating documents. The purpose of the TPPA is to enhance each of the countries’ economic 
development and that this may lead to improved social and health development. However, although 
there may be positive impacts on the health and wellbeing of Australians resulting from economic 
growth, there are also many ways in which the TPPA has the potential to have negative impacts on 
the health of Australians. This policy brief examines the potential impact of provisions proposed for 
the TPPA on the health of Australians, focusing on two specific issues: the cost of medicines, and the 
ability of government to take major steps to improve the health of Australians by regulating the 
areas of tobacco and alcohol policy. In each of these areas we trace some of the pathways through 
which provisions that have been proposed for the TPPA may impact on the health of the Australian 
population, and the health of specific groups within the population. We highlight the ways in which 
some of the expected economic gains from the TPPA may be undermined by health and economic 
costs. 
Concerning the cost of medicine we focus on how proposed provisions in the TPPA could impact the 
affordability of medicines through several different routes: by delaying the availability of cheaper 
generic medicines, by altering the operation of the Pharmaceutical Benefits Scheme (PBS) making it 
more difficult to keep costs down, and by enabling pharmaceutical companies to sue the 
government over its pharmaceutical policies. These changes would increase the cost of the PBS for 
the government and taxpayers. Strategies to compensate for an increase in medication costs include 
increased cost-sharing, with patients assuming higher co-payments, or funding reallocation from 
other parts of the healthcare system.  
Provisions in the TPPA may impact the ability of Government to enforce existing policies and 
implement new policies that support public health. Australia is internationally recognised for the 
success of comprehensive strategies to reduce tobacco smoking.  And more recently, there are 
multiple initiatives being proposed to achieve similar success to reduce harmful use of alcohol. We 
outline several of the many provisions in the TPPA that could affect tobacco and alcohol policies in 
Australia.  
Concerning tobacco these include an investor-state dispute settlement mechanism clause in the 
TPPA would provide more opportunities for tobacco companies to sue the Australian government 
over strong tobacco control measures. Rules about ‘indirect expropriation’ (i.e. depriving an investor 
of property, which, if broadly defined, can include intellectual property such as trademarks) and ‘fair 
and equitable treatment’ provide additional grounds for corporations to argue that their assets are 
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being unfairly affected by government policies and laws. Provisions in the TPPA may impact the 
Government’s ability to implement effective alcohol control policies such as restrictions on liquor 
licences, bans or limits on alcohol advertising, and alcohol health warning labels. 
Concerning alcohol these include provisions in the Technical Barriers to Trade (TBT) Chapter of the 
TPPA which could limit possibilities for introducing innovative alcohol policies, such as requiring 
health warning labels. Provisions in the wine and spirits annex to the TBT Chapter may limit the 
options available to create a fully effective alcohol warnings scheme for wine and spirits. If Australia 
agrees to an investor-state dispute settlement (ISDS) mechanism applying to Australia, the alcohol 
industry will have access to a new legal channel to sue the Australian Government over alcohol 
policy decisions that adversely impact their investments. 
We conclude that while there is some potential for the TPPA to contribute to economic 
development, there is also significant risk that the economic gains which the TPPA may represent, as 
well as the health of the Australian community, will be threatened if certain proposed provisions are 
adopted for the TPPA. These include increased direct costs in terms of providing health care and 
increased use of hospitals, higher costs of obtaining pharmaceuticals, indirect costs associated with 
lost productivity across society, continuing or exacerbating inequalities in society, and worsening the 
health of Australia’s already vulnerable communities. 
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This policy brief is a preliminary output from the early stages of a Health Impact Assessment (HIA) of 
the Trans Pacific Partnership Agreement (TPPA). 
The TPPA is a regional trade agreement in the final stages of negotiation. Countries currently 
negotiating include Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, 
Singapore, Vietnam and the United States. The purpose of the TPPA is to enhance each of the 
countries’ economic development and that this, in turn, leads to improved social and health 
development. 
However, although there are likely to be positive impacts on the health and wellbeing of Australians 
resulting from economic growth, there are also many ways in which the TPPA has the potential to 
have negative impacts on the health of Australians. Some of these include reduced access to 
affordable medicines, reduced effectiveness of tobacco and alcohol policies, reduced food security 
and poorer nutrition, increased costs of providing public health services, and pressure on the 
physical environment. Despite these potentially severe, negative consequences, the negotiations are 
conducted under conditions of confidentiality for the TPPA. The public (and public health 
professionals) have no access to draft texts and limited 
information about the negotiations. 
The purpose of this brief is to inform the debate from a 
health perspective in the final stages of the 
negotiations, particularly during meetings of chief 
negotiators and ministers in February 2014.  
Health impact assessment, simply defined, is the 
process of identifying the future consequences of a 
current or proposed action on the community’s health. 
A detailed health impact assessment will be conducted 
during March and April 2014 to predict the potential 
impacts from the TPPA and develop recommendations 
about how actions related to the TPPA can improve the health of Australian communities.   
In this brief, we apply some of the principles of HIA to examine the potential impact of provisions 
proposed for the TPPA on the health of Australians, focusing on two specific issues: the cost of 
medicines, and the ability of government to regulate in the areas of tobacco and alcohol policy. In 
each of these areas we trace through some of the pathways through which provisions that have 
been proposed for the TPPA may impact on the health of the Australian population, and the health 
of specific groups within the population. We highlight the ways in which some of the expected 
economic gains from the TPPA may be undermined by health and economic costs (in terms of lost 
productivity or added health care expenses) if certain provisions are included in the final text.  
We do not claim that the health impacts identified in this brief will result from the TPPA. Much 
depends on the positions that nation states, including Australia, take in the negotiations and we 
INTRODUCTION 
This brief highlights the ways in 
which some of the expected 
economic gains from the TPPA 
may be undermined by health 
and economic costs in terms of 
lost productivity or added 
health care expenses. The focus 
is on two specific issues: the 
cost of medicines, and the 
ability of government to 
regulate in the areas of tobacco 
and alcohol policy. 
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The TPPA could impact the 
affordability of medicines through 
several different routes: by delaying 
the availability of cheaper generic 
medicines, by altering the operation 
of the Pharmaceutical Benefits 
Scheme making it more difficult to 
keep costs down, or by enabling 
pharmaceutical companies to sue 
the government over its 
pharmaceutical policies. These 
changes would increase the cost of 
the PBS for the government and 
taxpayers. 
 
believe that there is real potential to increase the positive impacts of the TPPA not only on economic 
development, but also on health and wellbeing. Our purpose is to highlight potential health (and 
economic) impacts that could arise if certain proposed provisions are included in the final TPPA. 
The two focus areas discussed in the brief are by no means the only areas where the TPPA may have 
an impact on the Australian community’s health. We have chosen these particular areas because 
they represent clear health concerns which affect the claims about the economic benefits of the 
TPPA. 
 
 
 
Proposed provisions in the TPPA could impact the affordability of medicines through several 
different routes: by delaying the availability of cheaper generic medicines, by altering the operation 
of the Pharmaceutical Benefits Scheme (PBS) making it more difficult to keep costs down, or by 
enabling pharmaceutical companies to sue the government over its pharmaceutical policies. These 
changes would increase the cost of the PBS for the government and taxpayers. Strategies to 
compensate for an increase in medication costs include increased cost-sharing, with patients 
assuming higher co-payments, or funding reallocation from other parts of the healthcare system [1].  
While there are many possible outcomes associated with the proposed TPPA provisions, this brief 
will consider just one potential scenario: potential increases in patient co-payments (i.e. the amount 
patients contribute towards the cost of a prescribed medicine).
Why do out-of-pocket medicine costs matter? 
 
Out-of-pocket expenses (such as patient co-payments) can be a barrier to prescription use [2, 3]. In 
2005, 22% of Australians reported skipping a dose or not filling a prescription due to cost [4]. In a 
2007 survey of patient behaviour, roughly 21% 
reported buying an over-the-counter medicine 
instead of a prescription, 48% asked their doctor 
for a cheaper medication, 18% used a medicine 
already at home rather than buy a new 
prescription, and 6% used a medication 
belonging to someone else [5]. All of these 
behaviours were significantly more likely to 
occur in patients who reported moderate to 
extreme financial burden from the cost of their 
prescriptions [5]. 
 
 
COST OF MEDICINES 
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The burden of higher cost-
sharing for prescriptions 
leads to financial strain on 
patients and can have 
significant health impacts. 
In the U.S., patients with 
higher cost-sharing for 
prescriptions had both 
poorer adherence to drug 
therapy, poorer health 
outcomes, and higher rates 
of hospitalizations and use 
of emergency services. 
 
Why are increases in out-of-pocket medicine costs 
important? 
 
The burden of higher cost-sharing not only leads to financial strain on patients, but also can have 
significant health impacts. In the U.S., patients with higher cost-sharing for prescriptions had poorer 
adherence to drug therapy, poorer health outcomes, and higher rates of hospitalizations and use of 
emergency services [6, 7]. Previous increases in the PBS co-payments have impacted medication use 
in Australia. In 2005, the PBS raised co-payments by 21%. A study of this increase found a decrease 
in dispensing of between 3% and 11% for 12 of the 17 medicines that were monitored. There were 
also significantly higher declines in prescription use for concessional patients than general patients 
[8]. The study found that the price increase led to a decline in dispensing of proton pump inhibitors 
(drugs commonly used to treat gastric acid conditions) across all geographical areas, indicating that 
the price change impacted not only disadvantaged populations but all Australians [8]. Although on 
the face of it reduced medicine use may appear to save money, it rather leads to more significant 
longer-term costs associated with more complicated and prolonged illness [6, 7].  
Increased costs of medicine also cause financial burden for patients which can impact their health.  
In a 2008 survey on patient behaviour, more than 75% of respondents said a price increase in co-
payments would cause financial difficulty.  However, despite the added financial burden most would 
continue prescribed medicine use. This indicates that the financial impacts of cost increases may 
impact other areas of life, such as food or housing,  than prescription use alone [9].  
How does this affect certain population groups? 
 
Generally women, elderly, cultural and linguistic minorities, and low-income populations report the 
most difficulty with financial barriers to prescription use [10]. Both geographically remote and low-
income populations have the lowest use of prescription 
medications [11]. This is especially relevant as many of 
these sub-populations, particularly Indigenous Australians, 
already have the poorest health [12-14]. Statins – a type of 
medication used to treat heart disease – are used the least 
in areas of economic disadvantage despite this group having 
the highest rates of cardiovascular disease [15].  People 
with chronic disease are also more vulnerable to price 
fluctuations. In a study of the financial burden of managing 
a chronic illness, 45% of Sydney households were unable to 
pay at least one medical or living expense in the past year. 
People who were economically disadvantaged spent more 
to manage their illness than those who were not 
experiencing economic hardship [16].   
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Intellectual property provisions 
in the TPPA potentially expand 
and extend patent monopolies, 
keep drug prices high for 
longer periods and delay the 
availability of generic 
medicines. The Australian 
Government’s position is that 
it will not accept anything in 
the TPPA that would adversely 
affect the Pharmaceutical 
Benefits Scheme. 
 
What are the TPPA provisions that have the potential to 
impact the cost of medicines? 
 
There are many different parts of the TPPA that may have implications for the cost of medicines. 
Below we explore the implications of the intellectual property chapter, an annex to the transparency 
chapter, and the investment chapter of the TPPA. However, it is important to note that other parts 
of the TPPA text, such as the regulatory coherence chapter, the transparency chapter and the 
technical barriers to trade chapter, may also contain provisions, including accountability and 
enforcement mechanisms that could also affect the cost of medicines. The provisions proposed for 
the TPPA will also affect access to medicines in developing countries in the region (such as Vietnam), 
and this has implications for the success of Australia’s aid programs in the region. However, in this 
policy brief our focus is on the health of Australians. 
Intellectual property (IP) chapter 
Leaked draft negotiating documents show the U.S. is seeking the inclusion of provisions that would, 
via a range of different mechanisms, expand and extend patent monopolies, keep drug prices high 
for longer periods and delay the availability of generic medicines [17-19].  
For example, a draft of the IP chapter leaked in December 2013 shows that the US is seeking to 
prevent countries from refusing to grant patents for minor variations to existing products even when 
there is no evidence of additional benefit [20]. This provision would encourage ‘evergreening’ of 
patents - a strategy patent holders use to extend their monopolies by gaining additional patents, 
thus preventing competition from cheaper generic versions for longer periods. 
Another provision proposed by the US would 
lengthen the term of patents to compensate for 
delays in issuing patents or in obtaining marketing 
approval [20]. In Australia, drug companies can 
already get patent term extensions of up to five years 
for new pharmaceutical products. But under the US 
proposal, patent term extensions would also be 
available for a wider range of patents, including for 
new methods of making or using pharmaceutical 
products [17]. 
The US is also seeking to lengthen the period during 
which generic manufacturers cannot use clinical trial data produced by the manufacturer to obtain 
marketing approval for a generic version of the drug (this is known as ‘data protection’ or ‘data 
exclusivity’). Under the Australia-US Free Trade Agreement, Australia must already provide at least 
five years of protection for a new pharmaceutical product. But the US is seeking at least three years 
of additional data protection for new uses of existing drugs [20], and up to twelve years for biologic 
products (drugs and other products such as vaccines that are derived from cells or tissues) [21]. 
These are just a few examples of the provisions sought by the US for the TPPA that would delay the 
availability of generic medicines and add to pharmaceutical expenditure in Australia. 
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A leaked draft of the investment 
chapter of the TPPA shows that it 
includes an investor-state dispute 
settlement mechanism which may 
allow pharmaceutical companies 
based in the U.S. or other TPPA 
countries to sue over 
pharmaceutical policies and laws. 
Even when such cases are 
unsuccessful, the threat of 
litigation may deter governments 
from implementing policies and 
laws. 
There has been considerable opposition to the US proposals by the other countries, and the current 
state of the negotiations on IP is unclear. The Australian Government’s position is that it will not 
accept anything in the TPPA that would adversely affect the Pharmaceutical Benefits Scheme [22]. 
However, commentary during the TPPA Ministers’ Meeting in Singapore in December 2013 
suggested that countries, including Australia, may have agreed to some of the IP provisions sought 
by the US [23]. These reports have not been confirmed.  
Healthcare transparency annex 
A draft US proposal for a TPPA Annex on ‘Transparency And Procedural Fairness For Healthcare 
Technologies’, leaked in 2011 [24] included provisions that would [17]: 
• Preclude therapeutic reference pricing, an important mechanism for ensuring that the prices paid 
for medicines reflect their clinical benefit (therapeutic reference pricing involves linking the price 
of a new medicine to other medicines that are already available for the same condition); 
• Introduce onerous obligations for transparency and information disclosure (facilitating 
pharmaceutical industry influence over decisions about which drugs to list and how much to pay 
for them); 
• Extend opportunities for manufacturers of pharmaceuticals and medical devices to  influence 
decision making regarding listing, pricing and reimbursement; 
• Include review/appeals processes which would enable the overturning of listing and pricing 
decisions made by health expert bodies; 
• Legalize direct-to-consumer advertising via the internet (which is currently prohibited in Australia 
due to concerns about the effect it can have on rational prescribing); and 
• Establish mechanisms for ongoing input by US trade officials into decision making about the PBS. 
This proposal was reportedly rejected by the other countries [1]. In December 2013, leaked 
negotiating documents suggested that Australia and Japan had worked with the US on a revised 
proposal [25]. Recent commentary [26] suggests that the recent revision may be more similar to the 
provisions in the Australia-US Free Trade Agreement than the original US proposal, which would 
mean less extensive changes to Australia’s PBS than the original US proposal. However, there are still 
considerable risks involved in negotiating provisions that will affect the PBS. 
Investment chapter 
A draft of the investment chapter of the TPPA leaked in 2012 [27] indicated that an investor-state 
dispute mechanism was being negotiated for the 
TPPA. This mechanism enables foreign corporations 
to sue governments in international tribunals when 
they perceive that a government policy or law 
reduces the value of their investment. The current 
Coalition Government has indicated that it is 
considering negotiating an Investor-state dispute 
settlements (ISDS) mechanism applying to Australia. 
It is possible that an ISDS mechanism in the TPPA 
may allow pharmaceutical companies based in the 
U.S. or other TPPA countries to sue the Australian 
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Australia has a strong track 
record for supporting 
polices that protect public 
health at State and 
Commonwealth levels. 
Many chapters of the TPP 
could affect policy 
formulation and the 
innovation required to 
protect and promote 
population. 
government over pharmaceutical policies and laws. For example, Eli Lilly and Company, a U.S.-based 
pharmaceutical company, is suing the Government of Canada for CAD $500 million over Canadian 
court decisions to revoke patents on two drugs [28]. Even when such cases are unsuccessful, the 
threat of litigation may deter governments from implementing policies and laws.
 
 
 
Provisions in the TPPA may impact the ability of Government to enforce existing policies and 
implement new policies that support public health. Preventative health strategies such as Australia: 
The Healthiest Country by 2020, launched by the Preventative Health Taskforce, highlight the 
importance of consistent effort from Government to prioritize innovative and effective programs 
and policies. The cost to the healthcare system from health 
effects of tobacco, alcohol, and obesity – three target 
areas of the preventative health strategy – is estimated to 
be roughly $6 billion per year, and lost productivity as a 
result is estimated at almost $13 billion [29, 30]. Australia 
is internationally recognised for the success of 
comprehensive strategies to reduce tobacco smoking.  And 
more recently, there are multiple initiatives being 
proposed to achieve similar success to reduce harmful use 
of alcohol.  Evidence shows that shorter trading hours for 
alcohol, preventing harmful promotion of alcohol, and 
alcohol health warning labels work to reduce the harmful use of alcohol [31]. As well, smoke-free 
policies for public spaces, and tobacco plain packaging have been shown to contribute to reducing 
the prevalence of smoking [32]. Some of these policies are in place, such as plain packaging of 
tobacco, and some are under consideration by Government, such as alcohol health warnings. This 
section will look at public health strategies related to tobacco and alcohol, and the impacts on these 
policies that may result from potential provisions in the TPPA. 
 
 
 
Provisions in the TPPA may have an impact on Australia’s tobacco plain packaging laws and our 
capacity to introduce other progressive tobacco control policies in the future. 
ABILITY OF GOVERNMENT TO 
REGULATE IN THE AREAS OF TOBACCO 
AND ALCOHOL POLICY 
TOBACCO POLICY 
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Why does tobacco control matter? 
 
Smoking is currently Australia’s largest cause of preventable death and illness [33-35]. Eight percent 
of the disease burden in the general population is attributable to smoking, and it is responsible for 
20% of deaths in Indigenous Australians [36, 37]. In 2012, over 16% of the adult population (2.8 
million) smoked daily [38]. The prevalence of smoking in Australia has steadily declined over the past 
decade from roughly 22% in 2001 to 19% in 2008 [38]. However, it was estimated that the social cost 
-- through lost productivity, healthcare costs and others -- of smoking in Australia in 2005 was over 
$31 billion [29, 35]. 
What are effective tobacco control policies? 
 
In recent years the Commonwealth and State Governments have adopted many progressive smoking 
prevention policies and strategies and have demonstrated a commitment to a reduction in smoking 
prevalence through broad tobacco control measures. Many of these have been public policy 
measures – the cumulative effect of which has been to achieve consistently declining rates of 
tobacco use [38-40].   
Recently, Australia showed international leadership in introducing plain packaging on tobacco 
containers, adding to the range of existing public policies. Plain packaging is the removal of colours, 
logos, and other marketing materials from tobacco containers, and the placement of enlarged 
graphic health warnings [41]. Research has shown that limiting package design decreases 
perceptions about the desirability of smoking [42-44]. Other research has shown knowledge of risks 
of tobacco use leads to higher rates of quitting [32, 45, 46]. Using tobacco packages to display health 
warnings has also been shown to increase awareness of the health effects of smoking and increase 
cessation behaviour [33, 43, 47-52]. 
Innovative policies, such as the plain packaging strategy, are important for protecting public health 
by reducing the uptake of smoking and encouraging current smokers to quit. A European study 
found that quit ratios were the highest in countries with the most progressive tobacco control 
policies [43]. According to the Australian National Preventative Health Taskforce Tobacco Work 
Group “…smoking in the population as a whole will not reduce without vigorous and consistent 
action by governments and health organisations” [32, p.1].  
How does this affect certain population groups? 
 
There are critical disparities in various ethnic and socioeconomic groups related to tobacco use. 
Smoking rates among Indigenous Australians are more than double those in the rest of the 
population [33, 35, 36]. Rates of smoking are also high amongst vulnerable populations such as 
homeless people [53], people who use drugs [54], incarcerated people [33], people with low 
socioeconomic status [33, 35] and people with mental illness [55]. Children in low socioeconomic 
status (SES) households are more than four times more likely to be exposed to smoke in the home 
than children of higher SES households [33]. Smoking prevalence has declined least in the most 
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Leaked TPPA provisions outline 
protections for investors 
including rules about ‘indirect 
expropriation’ and ‘fair and 
equitable treatment’. These 
rules provide additional 
grounds for corporations to 
argue that their assets are 
being unfairly affected by 
government policies and laws. 
disadvantaged communities [33]. Broad level policies have been shown to be most effective in 
reducing inequities in smoking prevalence [56]. During periods of low funding for tobacco control 
measures in Australia (1990–1996), smoking prevalence increased amongst 12 to 15 year-olds with 
the greatest increase among low SES students. In contrast, during periods of high funding (1997-
2005) smoking decreased sharply with consistent decreases amongst all SES groups [33].  
What are the TPP provisions that have the potential to 
impact the government’s ability to regulate for tobacco? 
 
Many chapters of the TPPA could affect tobacco control policies in Australia. The summary below 
focuses on the chapters most commonly identified by legal experts as presenting problems for 
tobacco control. Importantly multiple chapters may interact, with amplified effects on tobacco 
control [57]. 
A leaked draft of the investment chapter of the TPPA [27] shows that it includes an investor-state 
dispute settlement (ISDS) mechanism. The tobacco industry has used similar mechanisms in other 
trade and investment agreements to sue the governments of Australia and Uruguay over their 
strong tobacco control measures [58]. Philip Morris Asia 
is using the ISDS clause in an investment agreement 
between Australia and Hong Kong to seek  compensation 
(possibly amounting to billions of dollars)  over its 
tobacco plain packaging laws [59]. While the 
government is expected to win this case, an ISDS clause 
in the TPPA would provide more opportunities for 
tobacco companies to sue. The current Government has 
made it clear that it is prepared to negotiate an ISDS 
mechanism applying to Australia [60].  
The leaked draft TPPA investment chapter [27] also includes other protections for investors 
including rules about ‘indirect expropriation’ (i.e. depriving an investor of property, which, if broadly 
defined, can include intellectual property such as trademarks) and ‘fair and equitable treatment’. 
These rules provide additional grounds for corporations to argue that their assets are being unfairly 
affected by government policies and laws [61, 62]. For example, Philip Morris Asia is claiming that 
the Australian Government has expropriated its intellectual property by preventing it from 
displaying trademarks and other branding on tobacco packaging [59].  
Rules related to trademarks in the intellectual property chapter of the TPPA [20] may be 
interpreted to provide greater rights to tobacco companies to use their trademarks than those 
provided by the World Trade Organization [63]. This could provide grounds for industry challenges to 
removal of branding from products (as in tobacco plain packaging). 
Provisions in the Regulatory Coherence Chapter [24] include requirements for governments to 
provide opportunities for stakeholder input into policy-making.  The Transparency Chapter could 
also reinforce these opportunities [57]. This potentially undermines the requirement of the World 
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Making alcohol more expensive 
and less available, and banning 
alcohol advertising, are highly 
cost-effective strategies to 
reduce harm. Provisions in the 
leaked Technical Barriers to 
Trade (TBT) Chapter may make it 
more difficult for countries to 
make a case for introducing 
innovative alcohol policies, 
particularly where the evidence 
base is still developing. 
 
Health Organization’s Framework Convention on Tobacco Control [64] that tobacco control policies 
be protected from tobacco industry interests.  
Provisions in the chapter on Cross-border Services may affect services related to the packaging, sale, 
distribution and advertising of tobacco products  [61]. These provisions might affect tobacco control 
policies such as bans on advertising, or licensing of retailers and distributors [61], policies which have 
proven effectiveness.  
The Technical Barriers to Trade chapter may also affect the way governments set tobacco control 
regulations, standards and guidelines [61]. 
In 2013, the Malaysian Government tabled a proposal to “carve out” (i.e. exclude) tobacco from the 
TPPA [65]. This would mean tobacco control measures (such as tobacco plain packaging) would not 
be covered by any of the provisions in the TPPA. However, reports suggest that the Australian 
government is not supporting this proposal. 
 
 
 
 
Provisions from the TPPA may impact the Government’s ability to implement effective alcohol 
control policies such as restrictions on liquor licences, bans or limits on alcohol advertising, and 
alcohol health warning labels.  
Why does alcohol control matter? 
 
Alcohol contributes towards 4% of the world’s disability adjusted life years, or years lost due to 
alcohol-related injury or death. This is approximately the same proportion as tobacco (4.1%) [66]. 
Alcohol is associated with significant health effects to 
the brain, heart, liver and other organs, as well as 
social and psychological impacts [67]. More than 3.7 
million Australian adult drinkers are at risk for 
alcohol-related injury or illness over their lifetime 
based on their current rates of alcohol consumption 
[40]. In Australia, alcohol-related trauma and abuse 
has increased [40]. In a recent survey, over 13% of 
drinkers reported driving under the influence and 
5.7% reported verbally abusing someone. 
Approximately 22% of drinkers reported taking part 
in a potentially harmful activity while under the 
influence [40]. 
 
ALCOHOL POLICY 
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What are effective alcohol control policies? 
 
Systematic reviews and meta-analyses show that policies regulating the environment in which 
alcohol is marketed (particularly its price and availability) are effective and cost-effective in reducing 
alcohol-related harm [68, 69].  There is also evidence to support alcohol health warnings as an 
intervention to prompt target groups to discuss the health effects of drinking [70], increase health 
awareness of harm from drinking [71, 72], and to reduce drink-driving behaviour as a result of a 
drink-driving warning messages [73].  Warning labels have the potential to influence behaviour, but 
this depends on their design and message [74, 75].  
Alcohol marketing – via mainstream media, linking alcohol to social and sporting events, and direct 
marketing campaigns – has been shown to influence whether people drink and how much they 
drink, particularly for young people [31]. Banning of alcohol advertising, drink-driving 
countermeasures, licensing controls and individually-directed interventions to drinkers already at 
risk are considered cost-effective approaches [68, 76].  
Alcohol licensing is one measure that can be used to restrict consumption of alcohol through limiting 
the hours or days alcohol is available for purchase. State and Local Governments are responsible for 
the liquor licenses, planning laws and other restrictions that impact alcohol outlet density. Alcohol 
outlet density has been found to have an association with drink-driving and motor vehicle accidents 
[77-79]; pedestrian injury [80]; child maltreatment [81, 82]; and rates of sexually transmitted 
infection [83]. A study in Perth found that extending the trading hours for sale of alcohol was 
associated with an increase in the level of violent assault [84]. Some longitudinal evidence has 
shown that alcohol outlet density impacts rates of violence [85]. In one study, the authors estimated 
that an average reduction of one bar for each of the 581 postal codes analysed would have resulted 
in 209 fewer assaults [86].  
 
How does this affect certain population groups? 
 
There are apparent differences in alcohol consumption among various racial and geographical 
populations. People living in remote or very remote areas consume alcohol at risky levels greater 
than people living in major cities. Although Indigenous populations are more likely to abstain from 
drinking versus non-Indigenous, they are also 1.5 times more likely to consume alcohol at risky levels 
[40]. People with higher socioeconomic status (SES) are more likely to drink at high-risk levels than 
people with lower SES, yet people with lower SES have higher rates of death and disability due to 
alcohol [31, 40].    
There is evidence that low socioeconomic populations are more likely to be influenced by alcohol 
outlet density [87]. This implies that increases to alcohol outlet density may adversely impact 
vulnerable populations.  
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If Australia agrees to an investor-
state dispute settlement (ISDS) 
mechanism applying to Australia, 
the alcohol industry will have 
access to a new legal channel to 
sue the Australian Government 
over alcohol policy decisions that 
adversely impact their 
investments. 
 
What are the TPP provisions that have the potential to 
impact the government’s ability to regulate for alcohol?  
 
There are many chapters in the TPP that may impact on government’s ability to regulate for alcohol. 
Below, we discuss some of the main chapters of concern. 
If provisions in the Technical Barriers to Trade (TBT) Chapter of the TPPA repeat, or extend beyond 
those in the World Trade Organization’s TBT Agreement, it may be more difficult for countries to 
make a case for introducing innovative alcohol policies, such as requiring health warning labels, 
limiting the health or other claims which alcohol manufacturers can make about their products, or 
restricting the alcohol content of certain products. This is likely to be a problem where the evidence 
base for the intervention is still developing [62].  
Provisions in the wine and spirits annex to the TBT Chapter may limit the options available to create 
a fully effective alcohol warnings scheme for wine and spirits. If it allows manufacturers to meet the 
labelling requirements of the importing country by putting a ‘supplementary label’ on the container, 
this may effectively prevent governments from mandating an effective warning scheme [88]. 
Rules related to trademarks in the Intellectual Property Chapter of the TPPA [20] may be 
interpreted to provide greater rights to alcohol companies to use their trademarks than those 
provided by the World Trade Organization. This 
could provide additional barriers to implementation 
of an effective health warning system.  
Rules included in the Cross-Border Services Chapter 
may prohibit governments from introducing bans or 
limits on the number and size of services supplied 
across borders  [62]. This might affect state and 
territory attempts to restrict the number of licensed 
alcohol outlets per geographic area. It might also 
inhibit the government from restricting alcohol 
advertising, particularly advertising via the internet or from broadcasters outside Australia.   
If Australia agrees to an investor-state dispute settlement (ISDS) mechanism applying to Australia, 
the alcohol industry will have access to a new legal channel to sue the Australian Government over 
alcohol policy decisions that adversely impact their investments.  Investor protections may extend to 
trademarks, licenses and distribution agreements as well as direct investment in alcohol 
manufacturing, retail and distribution [62].  
Rules related to trademarks in the Intellectual Property Chapter of the TPPA [20] may be 
interpreted to provide greater rights to alcohol companies to use their trademarks than those 
provided by the World Trade Organization. This could provide additional barriers to implementation 
of an effective health warning system.  
The general exceptions for the TPPA are likely to be based on the WTO exceptions. While these 
exceptions can be helpful in some disputes, they do not prevent disputes being raised and the limits 
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in the evidence base which necessarily exist with novel public health interventions might create 
difficulties in using the exceptions.  
 
 
 
Sustainable economic development brings potential improvements to health and wellbeing. There 
may be potential for the TPPA to contribute to economic development, higher standards of living 
and better health in Australia. However, there is a risk that the economic gains which the TPPA may 
represent, as well as the health of the Australian community, will be threatened if certain proposed 
provisions are adopted for the TPPA. This brief has presented evidence about some of the economic, 
health and social costs associated with medicines, alcohol and tobacco which could eventuate from 
the TPPA. These include increased direct costs in terms of providing health care and increased use of 
hospitals, higher costs of obtaining pharmaceuticals, indirect costs associated with lost productivity 
across society, continuing or exacerbating inequalities in society and worsening the health of 
Australia’s already vulnerable communities. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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